@theoc
The vibe I picked up after the Azer-cel acquisition is that the quickest path to FDA registration is to target 2nd/3rd line treatment after patients have failed off the major existing drugs (SOC). That’s a setting where there are no standard treatment options so, there would be no need for expensive long running Ph3 head to head trials as Vaxinia could initially slot in as 2nd/3rd line SOC, possibly with accelerated approval. That would pave the quickest path to revenue which will bring about much better terms for a licensing agreement or acquisition.
- Forums
- ASX - By Stock
- Ann: VAXINIA and HER-Vaxx featured at the AACR Annual Meeting
@theocThe vibe I picked up after the Azer-cel acquisition is...
-
- There are more pages in this discussion • 278 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IMU (ASX) to my watchlist
|
|||||
Last
5.9¢ |
Change
0.005(9.26%) |
Mkt cap ! $433.6M |
Open | High | Low | Value | Volume |
5.5¢ | 5.9¢ | 5.4¢ | $1.489M | 25.99M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 35252 | 5.9¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
6.0¢ | 1753430 | 24 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 717241 | 0.058 |
8 | 1860543 | 0.057 |
3 | 1067860 | 0.056 |
20 | 2643992 | 0.055 |
6 | 1127777 | 0.054 |
Price($) | Vol. | No. |
---|---|---|
0.060 | 1095176 | 20 |
0.061 | 520305 | 5 |
0.062 | 290000 | 4 |
0.063 | 100000 | 1 |
0.064 | 217000 | 3 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |